Table 3B. Univariate and multivariable analysis of predictors of PFS in the 69 patients with hyponatremia at the start of first-line therapy for locally advanced or metastatic NSCLC.

PROGRESSION-FREE SURVIVAL IN HYPONATREMIC PATIENTS
	Univariate Cox Regression		Multivariable Cox regression
	HR (95%CI)	p-value	HR (95%CI)	p-value
Age (≥ 70y vs. < 70y)	0.91(0.44−1.85)	0.789
Gender (F vs. M)	0.64 (0.30−1.36)	0.250
ECOG-PS (≥ 2 vs. < 2)	1.53 (0.66−3.54)	0.322
Smoke status (N vs. Y)	0.52 (0.15−1.74)	0.288
Tumor Stage (IV vs. III)	1.55 (0.73−3.30)	0.259
Histology (AC vs. non-AC)	0.56 (0.28−1.11)	0.097	0.70 (0.33−1.48)	0.359
EGFR Status (MT vs. WT)	0.62 (0.08−4.57)	0.641
Sodium Normalization (N vs. Y)	2.61 (1.22−5.57)	0.014	2.22 (1.02−5.04)	0.047

Significant values are reported in bold.

AC = Adenocarcinoma; CI = confidence interval; ECOG-PS = Eastern Cooperative Oncology Group Performance Status; EGFR = Epidermal growth factor receptor; F = female; HR = hazard ratio; M = male; MT = mutated status; WT = wild-type status